Recent work from our laboratory has demonstrated that human white blood cells make morphine and that substances of abuse, Le, nicotine, alcohol and cocaine have the ability to release this endogenous substance, suggesting a common mechanism of action. We now demonstrate that the nicotinic process is more complex than formerly envisioned. The incorporation rate of 125I-labeled morphine into PMN and MN are 7.85±0.36%, 1.42±O.19%, respectfully, suggesting in MN this process is of low activity. Separate incubations of PMN with varying concentrations of nicotine or the nicotine agonist epibatidine resulted in a statistically significant enhancement of 125I-trace labeled morphine released into the extracellular medium. In order to ascertain the specificity of the nicotine stimulated morphine release the following experiments were performed. Co-incubation of hexamethonium dichloride (5 Jig/ml and at 10 Jig/ml), which preferentially blocks nicotinic receptors at autonomic ganglia, with nicotine, exerted a very weak inhibitory effect Coincubation of u-BuTx or atropine or chlorisondamine diiodide or dlhydro-jl-erythroidine hydrobromide, an a4p2 receptor antagonist, did not block nicotine induced morphine release alone or in combination, suggesting either the response was not specific or it was mediated by a novel nicotinic receptor. Human leukocyte total RNA isolated from whole blood were analyzed, using the Human Genome Survey microarray (Applied Biosystems), for cholinergic receptor expression. PMN nicotinic receptor gene expression was present and contained numerous variants (eight). The number of variants suggests that indeed a novel nicotinic receptor may be mediating this effect, while simultaneously demonstrating the significance of the cholinergic receptor expression in these immune cells.
Recently, it was demonstrated that normal human white blood cells (WBC) contain and have the ability to synthesize morphine and release it into the microenvironment (I). Similar findings were reported in invertebrate ganglia (2) . Taken together, these studies provide evidence that the synthesis of morphine by various tissues and diverse animals is more widespread than previously thought and now includes human immune cells.
Importantly, in separate incubations the pooling of Mytilus edulis (invertebrate marine bivalve) pedal ganglia and Homarus americanus (lobster) nerve cord with ethanol, cocaine, or nicotine resulted in a statistically significant enhancement of 125I-trace labeled morphine release into the extra-cellular medium in a concentration dependent manner (3) . The stimulatory effects of ethanol, nicotine, and cocaine on cellular expression and release of endogenous morphine suggest convergent mechanisms underlying the reinforcing and addictive properties for a variety of drugs of abuse. In examining the cholinergic process further, both nicotine and epibatidine, a nicotine agonist, promoted evoked release of 125I-trace labeled morphine that is selectively linked to the activation of invertebrate nicotinic receptors based on pharmacological inhibition by a bungarotoxin (u-BuTx), not other antagonists (4) . Epibatidine promoted release at concentrations 2-3 orders of magnitude higher than nicotine, demonstrating further the specificity of nicotine in this regulatory process (4) .
In this report, we extend the nicotine observations to include human WBC, given the parallels associated with morphine cellular processes (1-5). We demonstrate that nicotine stimulates the release of endogenous morphine via a-BuTx insensitive mechanism in human WBC, providing a new understanding of substance abuse processes, while simultaneously providing a rationale for using WBC as a model cellular system for this phenomenon.
MATERIALS AND METHODS
Human blood was obtained from the Long Island Blood Services (Westbury, NY).
Human heparinized whole blood was immediately separated using 1-Step Polymorphs (Accurate Chemical and Scientific Corporation, Westbury, NY) gradient medium. Five ml of heparinized blood was layered over 5 ml of polymorphs in a 14 ml round-bottom tube and then centrifuged for 35 min at 500 x g in a swinging-bucket rotor at 18°C. After centrifugation, the lower band consisting of polymorphonuclear cells (PMN) were harvested in 14 ml tubes and then washed with 10 ml phosphate buffered saline (PBS) (Invitrogen, Carlsbad, CA) by centrifugation for 10 min at 400 x g.
A two-way ANOYA was used for statistical analysis comparing control (L-tryptophan exposed) to drug exposed cells. Each experiment was performed 4 times. The mean value was combined with the mean value taken from 4 other replicates. The medium containing the PMN was then separated after and before drug exposure at varying concentrations for I h. Cells were washed and the endogenous morphine content was determined.
Morphine Determination
The morphine extraction, isolation and identification and quantification protocols were performed as described elsewhere in great detail over the past 15 years (6) . In these experiments representative samples were subjected to this technique and used as an additional method to ensure what was being measured was indeed morphine. Several blank high pressure liquid chromatography (HPLC) purifications were performed between each sample to prevent residual morphine contamination remaining on the column. Furthermore, invertebrate molluscan mantle tissue was run as a negative control, demonstrating a lack of contamination (7) . All solutions, media etc, were also examined for any presence of morphine. The results of these tests revealed a lack of morphine contamination.
Radioimmuno-assay (RIA) determination:
Quantification of tissue concentrations of morphine employed a commercially available RIA kit obtained from Diagnostic Products Corporation (USA) [4, 8, 9, 15, 16] . The solid-phase RIA employs immobilized anti-morphine serum and 1251-labeled morphine as the radiolabeled tracer at an optimal specific activity of approximately 130 Ci/mmol. The highly sensitive RIA reliably quantifies morphine concentrations as low as 30 fmol/IO /ll aliquot of tissue extract (6) (7) (8) (9) (10) .
Ex vivo '25I-trace labeled morphine release from
WEe White blood cells (PMN or MN 10 million/ml) were bathed in medium containing purified RIA grade 1251-labeled morphine at a concentration of 0.10 /lCi/ml equivalent to a molar concentration of approximately 10-10M for 45 min. After labeling with '251-labeled morphine, WBC aliquots were extensively washed with medium to achieve basal levels of radioactivity in the extracellular medium equivalent to 20 cpm/ml. A representative assessment of labeling efficiency indicated that approximately 2.0 ± 0.9% for WBC of total 1251-labeled morphine in the incubation medium was incorporated into individual tissue pools of endogenous morphine.
Based on pre-determined values of I pg morphine equivalent to 10 fmol morphine/mg wet weight tissue, a first approximation of the 125 1 trace-labeled intracellular morphine pool indicates a ten to hundred fold dilution of high specific activity 1251-labeled morphine to achieve an effective specific activity of 10 Ci/mmol. An estimated specific activity of 10 Ci/mmol allows us to reliably quantify as little as 5% (control average 29.7 ± 8.1%) of the total tissue content of 125 1 trace-labeled morphine released into the extra-cellular medium following pharmacological challenge. The validity of the morphine release assay is confirmed by HPLC and antibody binding analyses of 1251-labeled morphine extracted from tissue and release medium indicating an 87% overall recovery of chemically authentic 1251-labeled morphine tracer.
Prior to addition ofdrugs, tissues were incubated with I ml medium and 0.2 ml of 1251-labeled morphine in a 1.5 ml polypropylene micro centrifuge tube for 45 min. Total cpm in 1.2 ml of medium plus two I ml washes was quantified using a Wallac Wizard 3" 1480 gamma counter (Perkin Elmer, Gaithersburg, MD). For each pharmacological trial, a selected concentration of nicotine, ethanol or cocaine was added to I ml of fresh medium and incubated with WBC for 10 min. At the end of each drug trial, total cpm in I ml of medium and residual radioactivity in the WBC were quantified and used to estimate the fraction of 1251-trace labeled morphine released as a function of total tissue content of 1251-trace labeled morphine pools. On average, residual levels of radioactivity in control tissues were always greater than 65% of total cpm, whereas in treated tissue differences depended on the amount of drug added, indicating regulated release of 125 1 trace-labeled morphine by pharmacological agents (data not shown). All drugs and chemical were purchased from Sigma (St. Louis, Mo) and ethanol from Fisher Scientific.
Microarray Analysis
Isolation ofTotal RNA Human leukocytes were pelleted by centrifugation and total RNA was isolated with the RNeasy Protect Mini Kit (Qiagen, Stanford, CA). Pelleted cells were resuspended in buffer RLT and homogenized by passing the lysate 5 times through a 20-gauge needle fitted to a syringe. The samples were then processed following the manufacturer's instructions. In the final step, the RNA was eluted with 50 J.lI of RNase-free water by centrifugation for I min at 10,000 rpm. Quality of the RNA was analyzed on a 1% agarose gel and the concentration by an RNA/DNA spectrophotometer (Amersham).
Applied Biosystems Expression Array Analysis
Applied Biosystems Human Genome Survey Arrays were used to analyze the transcriptional profiles of two leukocyte RNA samples (control and treated), following acute morphine exposure. The Applied Biosystems Human Genome Survey Array contains 31,700 60-mer oligonucleotides probes representing a set of 27,868 individual human genes and more than 1,000 control probes. Sequences used for microarray probe design are from curated transcripts from the Celera Genomics Human Genome Database (www.celeradiscoverysyste m.com), RefSeq transcripts that have been structurally curated from the LocusLink public database (http: //ncbi.nlm.nih.bov/LocusLink/refseq.html), high-quality cDNA sequences from the Mammalian Gene Collection (MGC) (http://mgc.nci.nih.gov) and transcripts that were experimentally validated at Applied Biosystems. The 60-mer oligo probes are synthesized using standard phosphoramidite chemistry and solid-phase synthesis and quality controlled by mass spectrometry. The probes are deposited and covalently bound onto a derivatized nylon substrate (2.5 x 3 inches) that are backed by a glass slides by contacting spotting with a feature diameter of 180 urn and space of > 45 urn between each feature. A 24mer oligo internal control probe (lCP) are co-spotted at every feature with 60-mer gene expression probe on the microarray.
Digoxigenin-UTP labeled cRNA was generated and linearly amplified from I ug of total RNA using Applied Biosystems Chemiluminescent RT-IVTLabeling Kit v 2.0 and manufacturer's protocol. Array hybridization (two arrays per sample), chemiluminescence detection, image acquisition and analysis were performed using Applied Biosystems Chemiluminescence Detection Kit and Applied Biosystems 1700 Chemiluminescent Microarray Analyzer following the manufacturer's protocol. Briefly, each microarray was first pre-hybridized at 55°C for I hr in hybridization buffer with blocking reagent. 16 J.lg of labeled cRNA targets were first fragmented into 100-400 bases by incubating with fragmentation buffer at 60°C for 30 min, mixed with internal control target (lCT, 24-mer oligo labeled with LIZ fluorescent dye) and hybridized to each pre-hybed microarray in a 1.5-ml volume at 55°C for 16 hr. After hybridization, the arrays were washed with hybridization wash buffer and chemiluminescence rinse buffer.
Enhanced chemiluminescent signals were generated by first incubating arrays with antidigoxigenin-Alkaline Phosphatase, enhanced with Chemiluminescence Enhancing Solution and finally adding Chemiluminescence Substrate. 8 images were collected for each microarray using the 1700 analyzer which is equipped with high-resolution, large-format CCD camera, including 2 "short" chemiluminescent images (5 seconds exposure length each) and 2 "long" chemiluminescent images (25 seconds exposure length each) for gene expression analysis, 2 fluorescent images for feature finding and spot normalization, and 2 QC images for spectrum cross-talk correction. Images were auto-gridded and the chemiluminescent signals were quantified, corrected for background and spot, and spatially normalized.
Algorithm AB 1700 Expression System software was used to extract assay signal, and assay signal to noise ratio values from the microarray images. Bad spots flagged by the software were removed from the analysis. The assay signal of the remaining set of 99.5% of genes was log transformed and quantile-normalized across arrays. To select expressed genes, the remaining set of 99.5% of genes was further filtered by standard AB 1700 signal to noise threshold (SIN greater than 3 in at least one sample). Cholinergic, nicotinic receptors that remained on the gene, list after these filtering methods were reported as being present.
Reverse Transcription-Polymerase Chain Reaction (Taqman Assay)
Based on the pharmacological data and microarray data, the gene showing the best signal to noise ratio was selected to be verified in leukocytes using real time polymerase chain reactions. The presence of the cholinergic, nicotinic receptor~4 (CHRNB4) in PMN was investigated using cells obtained from 25 ml of whole blood. PMN were placed in 600 III lysis buffer (RLT) and homogenized by pipetting in a I ml pipette tip. Total RNA was isolated following the procedures outlined in the RNeasy mini kit (Qiagen). RNA was eluted in 50 III RNAse-free Hp. RNA was evaluated by an Agilent 2100 bioanalyzer using a RNA nano chip (Agilent, Santa Clara, CA). 750 ng of total RNA was reverse-transcribed using random primers (Invitrogen, Carlsbad, CA). RNA was denatured at 95°C and reverse transcribed at 40°C for I hr using Superscript III Rnase H-Reverse Transcriptase (Invitrogen, Carlsbad, CA).
The cholinergic, nicotinic receptor~4 gene and the internal control gene,~-actin, were detected using the commercially available 20 X kits from Applied Biosystems (part numbers Hs 00609523_m I for CHRNB4 and 4333762F for ACTB). The 2X universal master mix (Applied Biosystems) containing the PCR buffer, MgCI 2 , dNTP's, and the thermal stable AmpliTaq Gold DNA polymerase, was used in the PCR reactions. PCR reactions used 3 III of cDNA in a total reaction volume of 50 Ill. Negative template controls were used to rule out any possible false positive results. The PCR reaction mixtures were transferred to a MicroAmp optical 96-well reaction plate and incubated at 95°C for 10 min to activate the Amplitaq Gold DNA polymerase and then run for 40 cycles at 95°C for 30 s and 60°C for I min on the Applied Biosystems 7500 sequence Detection System. All reactions were performed in triplicate and threshold cycle numbers were reported with standard deviations.
RESULTS
The intrinsically low basal levels of endogenous morphine in WBC does not allow direct quantification of morphine released into the extracellular medium using our standard analytical procedures. This necessitated development of a morphine release assay dependent on cellular uptake of high specific activity 125I-labeled morphine to achieve trace labeling of intracellular opiate alkaloid pools (3) .
Incorporation rate of 125I-labeled morphine into PMN and MN are 7.85 ± 0.36%, 1.42 ± 0.19%, respectively, with regard to the total incubated material, suggesting in MN this process is of low activity. Separate incubations of PMN with varying concentrations of nicotine or a nicotine agonist epibatidine resulted in a statistically significant enhancement of 125I-trace labeled morphine released into the extracellular medium in a concentration dependent manner (Fig. I) . Furthermore, nicotine stimulated morphine release is calcium dependent (Table I ), suggesting the presence of specific intracellular pools present for the release process. The threshold effects of nicotine on 125I-trace labeled morphine release were observed at 0.3 flM (0.05 fll of pure nicotine liquid/I ml of PBS) 13.65 ± 2.78% for MN, and 0.12 flM (0.02 ul of pure liquid nicotine for PMN/I ml of PBS) 12.42 ± 2.61% for PMN (Fig.  I) . The highest concentration of 6 flM nicotine was observed to promote a dramatic enhancement of 125I-trace labeled morphine release in both MN and PMN (greater than 150% increase as compared to control incubations, P < 0.00 I). Our results indicate that PMN are more sensitive to nicotine than MN. Incubation of epibatidine dihydrochloride, a potent nicotine receptor agonist (from 0.7 to 350 flM), significantly enhanced release of 125 1 morphine from the PMN (from 10.32 ± 3.57% to 45.42 ± 8.63%). Additionally, it appears that PMN respond to nicotine at lower concentrations than epibatidine, which also occurs in invertebrates (3).
To ascertain the specificity of the nicotine stimulated morphine release the following experiments were performed. Co-incubation of hexamethonium dichloride (5 ug/ml and at 10 flg/ ml and up to I mM), which preferentially blocks nicotinic receptors at autonomic ganglia, with nicotine, exerted a very weak inhibitory effect on nicotine stimulated release of morphine from PMN (reduction 6-10%; Fig. 2 ). Lower or higher dosages of hexamethonium dichloride did not affect nicotine stimulated morphine release. Co-incubation of a-BuTx at 0.625 flM and 1.25 flM (and up to I mM), which blocked invertebrate ganglia from (3), had no effect. Atropine and chlorisondamine diiodide, an irreversible, longlasting nicotinic acetylcholine receptor antagonist, at various concentrations (l 0-7-1 0-4 M) did not have any effect either. Additionally, dihydro-ferythroidine hydrobromide, a a4~2 and~4 receptor antagonist, at various concentration (l0-QO-3M), did not block nicotine induced morphine release alone and combination with other antagonists (c-BuTx, hexamethonium). Hexamethonium and atropine did not block nicotine, ethanol or cocaine stimulated 125 1 morphine release, further demonstrating the specificity of the response (Fig 3) . Co-incubation of u-BuTx, hexamethonium, chlorisondamine diiodide and atropine did not effect nicotine stimulated morphine release from PMN either (data not shown), suggesting either the response was not specific or it was mediated by a novel nicotinic receptor. Coincubation of nicotine, alcohol or cocaine at their effective concentrations only enhanced release by no more than 10%, suggesting these agents were working on the same pool, which has limitations (data not shown).
Microarray data
Human leukocyte total RNA isolated from whole blood were analyzed, using the Human Genome Survey microarray (Applied Biosystems), for cholinergic receptor expression. Nicotinic receptor gene expression was present and contained numerous variants. The expression analysis revealed the following variants: cholinergic receptor, nicotinic, alpha polypeptide 5 =CHRNA5; cholinergic receptor, nicotinic, alpha polypeptide~CHRNA4; chol.inergic receptor, nicotinic, alpha polypeptide 1 (muscle) =CHRNA1; cholinergic receptor, nicotinic, alpha polypeptide 1O=CHRNA10;
cholinergic receptor, nicotinic, beta polypeptide 4=CHRNB4; cholinergic receptor, muscarinic 4 =CHRNB2; cholinergic receptor, nicotinic, epsilon polypeptide=CHRM 1; and cholinergic receptor, nicotinic, beta polypeptide 2 (neuronal)=CHRM5. The number of variants suggests that indeed a novel nicotinic receptor may be mediating this effect, while simultaneously demonstrating the significance of the cholinergic receptor expression in these cells. These data are supported by other studies demonstrating the presence of nicotinic receptors on white blood cells (11).
Taqman assays
Based on the pharmacological and microarray data, we chose to verify the presence of the CHRNB4 in PMN, using real time polymerase chain reactions. The CHRNB4 gave the best signal to noise ratio in the microarray and its presence was further supported by the Taqman assay. The presence of the transcript was detected and the threshold cycle number obtained was 35.47 ± 0.05 at a threshold of 0.031 (Fig. 4) . The reference gene,~-actin, was also detected in the cDNA used in the assay (data not shown).
DISCUSSION
A novel observation of the present study links concentration-dependent effects of nicotine and epibatidine to endogenous morphine release from human WBC. It can also be ascertained from the present study that human WBC have the ability to accumulate labeled morphine into specific cellular pools that can then be induced, in a specific manner, to release a portion of this material upon exposure to nicotine. Additionally, these cells express numerous variations of the nicotinic receptor, explaining, in part, our inability to block the nicotine stimulated release ofmorphine with known nicotine antagonists. Taken together, the results suggest that nicotine may exert, in part, its pharmacological action because of its convergence on endogenous morphine signaling.
The addictive properties of nicotine are well documented and share similar behavioral sequelae described for opiate addiction (12) . Opiate and nicotine biochemical pathways appear somewhat parallel because the nicotine metabolic pathway is mediated by a CYP 450 isoform, namely CYP2A6 (13) , which is also the case for morphine biosynthesis (1). Interestingly, nicotine stimulates dopamine release and induces tyrosine hydroxylase mRNA expression in rat adrenal tissues as well as the release of morphine-6-g1ucuronide (14) (15) . Finally, the highly potent effects of nicotine 0.60 , -------------------, derived alkaloids found in brain tissues with weak binding activity for catecholamine receptors (19) (20) (21) (22) , suggesting another function (22) . Ethanol treatment increased THP levels in L-DOPA treated rat brains (23). Thus, the dopamine-derived alkaloids, suspected of playing a role in the pathogenesis of alcoholism, are more intimately linked in the rat brain (24) . It was found that neural structures were activated that were associated'with the so-called cerebral reward system and the ascending reticular activating system (25) . It appears likely that functional bases exist that facilitate coupling of a variety of drugs of abuse in reward and pain pathways to dopamine and endogenous morphine expression (26) (27) (28) (29) (30) (31) (32) .Interestingly, concomitantexposure to these agents did not significantly enhance morphine release, suggesting that this pool of opiate alkaloid is small and once activated, releases a precise amount of material.
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Moreover, long term smoking causes an up regulation of nicotinic receptors found on mouse WBC (33) . Interestingly, in mice that were administered nicotine, the u-BuTx site was not affected, supporting our preliminary data. Interestingly,epibatidine sites were found in smokers' WBC, not those of non-smokers, and they decreased (33) . In regard to substance abuse actions, we can speculated that immune dysfunction may occur because of, in part, the release of morphine into immune compartments whereby they initiate their down regulatory actions, compromising immune performance and surveillance (34) .
In conclusion, the results of the present study demonstrate that nicotine enhances WBC release of morphine. This result strongly suggests that the addictive properties of nicotine may arise from this ability to enhance morphine release from cellular stores, opening up a new level of understanding in substance abuse induced addiction and behavioral effects, as well as morphine regulation. In the past, these substances of abuse have been linked into a common pathway because of the common dopamine connection (35) (36) . Now, they are additionally linked because of their common effect on morphinergic processes (3) (4) (5) . It is highly significant that these substances of abuse converge on a similar process, providing a mechanism to initiate their pleasure and addicting actions with continued frequent use. in promoting radiolabeled morphine release from invertebrate nervous tissues are also observed in studies of nicotinic receptor-mediated analgesia at the spinal level (3, 16) . However, in the present report, given the insensitivities of various nicotine antagonists in these human tissues, even compared to the invertebrate system (3), evidence may be at hand for a novel nicotine receptor, i.e., splice variant, mediating this action in human tissues. In this regard, modification of the neuronal nicotinic acetylcholine receptor by deleting the a7 P2 or P4 subunit, produces CHRNB4, which exhibits lower affinities for epibatidine (17) and results in a loss of u-BuTx bindings sites (17) , supporting the present observations. Interestingly, these same receptors appear to modulate dopaminergic release and uptake at presynaptic sites and become impaired when exposed to other substances of abuse, specifically at the dopamine transporter site (18) . Taken together, because dopamine is a precursor of endogenous morphine biosynthesis (1-2), this alteration of dopamine release and uptake may also extend into morphine release as currently demonstrated.
We have also demonstratedthat ethanol and cocaine share the ability of nicotine to modify dopamine and morphine cellular processes (3) (4) (5) . This linkage also emerges from studies examining endogenous morphine precursors. Tetrahydroisoquinoline alkaloids (norlaudanosoline, tetrahydropapaveroline [THPD, in the past were regarded strictly as catecholamine-
